THE FLUOROQUINOLONES ciprofloxacin and ofloxacin are among the antimicrobial agents recommended by CDC for treating gonorrhea.1 In the United States, decreased susceptibility or resistance of strains of Neisseria gonorrhoeae to the fluoroquinolones has been reported only sporadically, and treatment failure associated within vitro resistance has not been described.2 However, the recent occurrence of resistant cases in Denver and Seattle suggests that clinically important resistance to the fluoroquinolones may be emerging. This report describes the findings of the investigations of these cases.
On May 24, 1995, a 35-year-old man presented to the Denver Public Health Sexually Transmitted Diseases Clinic with a history of dysuria and urethral discharge of approximately 1 month's duration. On March 11, he had returned from a ''dating tour'' of the Philippines during which he had had sexual contact with seven or eight female sex workers (ie, prostitutes); he denied sexual contact since returning to the
Fluoroquinolone Resistance in Neisseria gonorrhoeae--Colorado and Washington, 1995. Arch Dermatol. 1995;131(12):1367–1369. doi:10.1001/archderm.1995.01690240021003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.